MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, CGON had -$224,578K decrease in cash & cash equivalents over the period. -$132,480K in free cash flow.

Cash Flow Overview

Change in Cash
-$224,578K
Free Cash flow
-$132,480K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from sales and maturiti...
    • Proceeds from follow-on public o...
    • Stock-based compensation expense
    • Others
Negative Cash Flow Breakdown
    • Purchases of investments
    • Net loss
    • Acquisition, net of cash acquire...
    • Others

Cash Flow
2025-12-31
Net loss
-160,995
Depreciation and amortization
1,445
Stock-based compensation expense
26,676
Accretion of discount on short-term investments
1,014
Non-cash interest expense (income)
768
Non-cash lease expense
34
Prepaid expenses and other current assets
1,900
Accounts receivable, net
320
Inventory
444
Other assets
1,584
Accounts payable
-1,644
Accrued expenses and other current liabilities
8,655
Other liabilities
-487
Net cash used in operating activities
-132,346
Proceeds from sales and maturities of investments
844,139
Purchases of investments
1,067,860
Acquisition, net of cash acquired
21,967
Purchases of property and equipment
134
Net cash used in investing activities
-245,822
Proceeds from follow-on public offerings, net of issuance costs
147,450
Proceeds from exercise of common stock options
6,456
Stock issuance costs
316
Net cash provided by financing activities
153,590
Net (decrease) increase in cash and cash equivalents
-224,578
Cash and cash equivalents at beginning of period
257,068
Cash and cash equivalents at end of period
32,490
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from follow-onpublic offerings, net...$147,450K Proceeds from exercise ofcommon stock options$6,456K Net cash provided byfinancing activities$153,590K Canceled cashflow$316K Net (decrease)increase in cash and cash...-$224,578K Canceled cashflow$153,590K Proceeds from sales andmaturities of investments$844,139K Stock-based compensationexpense$26,676K Accrued expenses andother current...$8,655K Depreciation andamortization$1,445K Non-cash lease expense$34K Stock issuance costs$316K Net cash used ininvesting activities-$245,822K Canceled cashflow$844,139K Net cash used inoperating activities-$132,346K Canceled cashflow$36,810K Purchases of investments$1,067,860K Acquisition, net of cashacquired$21,967K Purchases of property andequipment$134K Net loss-$160,995K Prepaid expenses andother current assets$1,900K Accounts payable-$1,644K Other assets$1,584K Accretion of discount onshort-term investments$1,014K Non-cash interestexpense (income)$768K Other liabilities-$487K Inventory$444K Accounts receivable, net$320K

CG Oncology, Inc. (CGON)

CG Oncology, Inc. (CGON)